Taken together, our data indicate that high eosinophil counts prior to MAPKi initiation in patients with metastatic melanoma, but not ECP serum concentrations or functional differences in eosinophils, are associated with their response to targeted therapy. The gene discussed is RNASE3; the disease is metastatic melanoma.